Differential Lipidomic Characteristics of Children Born to Women with Polycystic Ovary Syndrome

Zhirong Zhang1,2,3,4,5†, Yue Liu1,2,3,4,5†, Jiali Lv6, Di Zhang1,2,3,4,5, Kuona Hu1,2,3,4,5, Jingyu Li1,2,3,4,5, Jinlong Ma1,2,3,4,5, Linlin Cui1,2,3,4,5* and Han Zhao1,2,3,4,5

1 Center for Reproductive Medicine, Cheeblo College of Medicine, Shandong University, Jinan, China, 2 Key laboratory of Reproductive Endocrinology of Ministry of Education, Shandong University, Jinan, China, 3 Shandong Key Laboratory of Reproductive Medicine, Shandong University, Jinan, China, 4 Shandong Provincial Clinical Research Center for Reproductive Health, Shandong University, Jinan, China, 5 National Research Center for Assisted Reproductive Technology and Reproductive Genetics, Shandong University, Jinan, China, 6 Department of Biostatistics, School of Public Health, Cheeblo College of Medicine, Shandong University, Jinan, China

Objective: To describe the lipidomic characteristics of offspring born to polycystic ovary syndrome (PCOS) women (PCOS-off) and assess the associations between differential lipids and clinical phenotypes.

Methods: Ultra performance liquid chromatography and mass spectrometry were performed on plasma samples from 70 PCOS-off and 71 healthy controls. The associations of differential metabolites with clinical phenotypes were examined by multiple linear regression.

Results: Forty-four metabolites were significantly altered in PCOS-off, including 8 increased and 36 decreased. After stratification according to sex, 44 metabolites (13 increased and 31 decreased) were expressed differently in girls born to PCOS women (PCOS-g), most of which were glycerolipids. Furthermore, 46 metabolites (9 increased and 35 decreased) were expressed differently in boys born to PCOS women (PCOS-b), most of which were glycerophospholipids. Significant associations of metabolites with weight Z-score and high density lipoprotein cholesterol were found in PCOS-off. Triglycerides, low density lipoprotein cholesterol, and thyroid-stimulating hormone were separately correlated with some lipids in PCOS-g and PCOS-b.

Conclusions: PCOS-off showed specific lipid profile alterations. The abnormal level of glycerophospholipids and sphingomyelin indicated the risk of glucose metabolism and cardiovascular diseases in PCOS-off. Some lipids, such as phosphatidylcholines, lysophosphatidylcholine and sphingomyelin, may be the potential markers. The results broadened our understanding of PCOS-offs’ cardiometabolic status and emphasized more specific and detailed monitoring and management in this population.

Keywords: lipid metabolism, lipidomics, polycystic ovary syndrome, offspring, cardiometabolic health
INTRODUCTION

As the most prevalent endocrine disorder in women of fertile age, polycystic ovary syndrome (PCOS) is known to be associated with several adverse metabolic outcomes, including obesity, dyslipidemia, insulin resistance, and type 2 diabetes (T2D) (1–3). In addition, women with PCOS are at increased risk of pregnancy complications, such as pregnancy-induced hypertension (PIH), gestational diabetes mellitus (GDM), pre-eclampsia, and premature delivery (4, 5). Aberrant metabolic pathophysiologi cal changes and increased pregnancy complications predispose PCOS women towards suboptimal intrauterine environments (2, 6–8). According to the Barker hypothesis, this may produce a detrimental impact on the cardiometabolic health of offspring born to PCOS women (PCOS-off) (9–12). Previous studies report multiple metabolic phenotypic changes in PCOS-off, including dyslipidemia (12, 13), but others have contradictory findings. Some studies find that triglyceride (TG), cholesterol (CHOL), high density lipoprotein cholesterol (HDL), and adiponectin levels in the cord blood of newborns of PCOS women are similar to those of controls (14, 15).

Metabolomics allows for large-scale qualitative and semi-quantitative analysis of numerous nutrients, small molecules, and metabolic intermediates and has proven to be a powerful tool for identifying alterations in metabolic pathways and novel biomarkers (16). As a branch of metabolomics, lipidomics offers opportunities to investigate a large range of lipids in biological tissues and fluids. Lipids are accepted to be directly involved in the pathogenesis of cardiovascular disorders, and are thus proposed as independent predictive markers (17, 18). Therefore, having a global view of lipid metabolism in PCOS-off will improve our understanding of the cardiometabolic health of this susceptible population and identify new biomarkers for early detection of metabolic aberrations.

The aim of this study was to assess lipid profiles in PCOS-off and determine the associations of plasma lipids in PCOS-off with their clinical phenotypes. The results could broaden our understanding of PCOS-offs’ cardiometabolic status and provide support for long-term monitoring and management.

MATERIALS AND METHODS

Study Populations

Children of PCOS women and control women were recruited in the clinics of Center for Reproductive Medicine, Shandong University based on a cohort study. PCOS diagnosis was defined according to the Rotterdam criteria. The inclusion criteria were women with two out of the following three characteristics, oligo-ovulation, clinical and/or biochemical hyperandrogenism and ovarian polycystic morphology in ultrasound examination. Patients with other causes of hyperandrogenism or oligomenorrhea, such as thyroid disease, hyperprolactinemia and Cushing’s syndrome, were excluded. The detailed diagnostic procedure was described in our previous study (12). A total of 141 children were enrolled with 70 PCOS-off and 71 controls. The control offspring were recruited according to their mothers’ age and BMI which were matched with the case group. The age of participated children ranged from 2.5 to 7.0 years old. Growth and development parameters were available in all children, including birth weight, gestational age, height, weight, diastolic blood pressure (DBP), systolic blood pressure (SBP). Blood samples from all children were available and used to measure endocrine and metabolic parameters, including follicle-stimulating hormone (FSH), luteinizing hormone (LH), estrogen (E2), prolactin (PRL), testosterone (T), thyroid-stimulating hormone (TSH), anti-Müllerian hormone (AMH), dehydroepiandrosterone sulfate (DHEA-S), free triiodothyronine (FT3), free thyroxine (FT4), antibodies against thyroglobulin (A-TG), antibodies against thyroid peroxidase (A-TPO), CHOL, fasting glucose (BG0), fasting insulin (INS0), TG, low density lipoprotein cholesterol (LDL), and HDL. The measurement methods and some calculation formulas, including BMI, the Z-score, homeostasis model for insulin resistance (HOMA-IR), and homeostasis model for β-cell function (HOMA-β), refer to our previous article (12).

Sample Processing

The blood samples were obtained in the morning with EDTA anticoagulant tube, and then placed at room temperature for 2 h. Thereafter, the blood samples were centrifuged at 2000 rpm, 4°C for 20 min, and the upper plasma was collected and stored at -80°C for lipidomics analysis.

Lipidomics Analysis

Lipid Extraction

100μl of plasma samples were transferred to a tube, and then added 900 μl of water, 2 ml of methanol and 0.9 ml of dichloromethane followed by vortexing. After adding 1.0 ml of water and 0.9 ml of dichloromethane, the mixture was emulsified by vortexing and then centrifuged at 3000 rpm, 4°C for 5 min. The lower dichloromethane layer was injected to a clean glass tube using a glass syringe. 2 ml of dichloromethane was added to the supernatants and centrifuged at 3000 rpm, 4°C for 5 min. Then the dichloromethane layers collected by twice centrifugations were mixed and evaporated to dryness in a vacuum concentrator. The residue was redissolved in 500μl of...
methanol/dichloromethane and centrifuged at 3000 rpm, 4°C for 5 min. Finally, the supernatant was collected for LC-MS analysis and the same amount of supernatant from each sample was collected and mixed as QC sample.

**Ultra Performance Liquid Chromatography Analysis**
The Waters ACQUITY UPLC I-Class system was used for chromatographic analysis. By using a 20 min linear gradient, samples were transferred onto a C18 CSH column (100 mm × 2.1 mm, 1.7 μm; Waters) at 45°C at a flow rate of 0.4 mL/min and then chromatographic gradient elution procedure was performed. Mobile phase buffer A consisted of acetonitrile/water (1/4), 0.1% formic acid, and 10 mM ammonium formate, and buffer B consisted of acetonitrile/isopropanol (1/9), 0.1% formic acid, and 10 mM ammonium formate.

**Mass Spectrometry Analysis**
The Xevo G2-S Q-TOF with an electrospray ionization (ESI) source (Waters, Manchester, UK) was used for mass spectrometry analysis. MS parameters were set as follows, ion source temperature, 100°C; desolation temperature, 400°C; capillary voltage, 2.5 kV; cone voltage, 24 kV; cone gas flow, 50 L/h; and desolation gas flow, 800 L/h (positive ion-mode); ion source temperature, 100°C; desolation temperature, 500°C; capillary voltage, 2.5 kV; cone voltage, 25 kV; cone gas flow, 10 L/h; and desolation gas flow, 600 L/h (negative ion-mode). Scan range of both modes was 100 to 1500 m/z.

**Data Processing and Metabolite Identification**
The raw data were processed using the Progenesis QI (Waters) software and the peak alignment, peak picking, and quantitation were performed by the parameters of each compound, including m/z, retention time, and peak area. The relative quantitative and accurate qualitative results of metabolites were obtained by matching the data with database including NIST (https://chemdata.nist.gov), HMDB (http://www.hmdb.ca), lipidmaps (http://www.lipidmaps.org), and an in-house lipid database. The mass deviation was 5 ppm. Then the compounds with coefficient of variance < 30% in QC samples and detectable in at least 50% of samples were selected as the final data for subsequent analysis. The data were then logarithm transformed and standardized using MetaX software. Multivariate statistical analysis, including principal component analysis (PCA) and partial least-squares discrimination analysis (PLS-DA), were performed to reduce the data dimension and conduct regression analysis. Variable importance in the projection (VIP) value from PLS-DA model, fold change (FC), and p value of t-test were used to identify differential metabolites. The threshold value was set as VIP > 1.0, FC > 1.2 or FC < 0.833 and p value < 0.05. After that, cluster analysis and volcano plots were used to show the metabolic patterns and overall distribution of metabolites of interest.

**Statistical Analysis**
All statistical analysis was performed using SPSS v26.0 software (SPSS Inc., Chicago, IL, USA). The tests of normality were performed by Kolmogorov Smirnov normality test, histogram, and Q-Q diagram. Continuous variables were presented as mean ± SD or median (interquartile range) according to the results of normality test. Categorical variables were presented as numbers (percentiles). Clinical characteristics were compared between study groups using t test, Mann–Whitney U test, or chi-square test.

In order to evaluate the associations between offspring phenotypes and differential metabolites, multiple linear regression analyses were performed, treating differential metabolites after natural logarithm transformation as predictors, and offspring phenotypes as outcomes. The missing values of metabolites were replaced by the minimum quantitative value of metabolites in all samples divided by twenty. Model 1 was an unadjusted model. Model 2 was adjusted for some anthropometric factors, including sex, age, and BMI. Model 3 was added some pregnancy and perinatal covariates (birth weight, mode of delivery, parity, and gestational age at delivery) based on model 2. Model 4 corrected all above variables plus other maternal and familial related factors, including maternal age, maternal BMI, education level, family monthly income (≤ ¥2999 = low, ¥3000–4999 = medium, ≥ ¥5000 = high), GDM, and PIH. Sex of offspring was not adjusted after gender stratification. Birth weight and children BMI were not adjusted in the linear regression analysis of body weight Z-score.

**Ethical Approval**
This study was approved by the institutional ethics committee of Shandong University. The ethics approval number was (NO. 2014[17]). The parents of the children signed the informed consent. The study conformed to the principles of the Declaration of Helsinki.

**RESULTS**

**Clinical Characteristics**
Baseline characteristics of the study population were summarized in Table 1. The study subjects consisted of 70 PCOS-off and 71 healthy controls with the percentages of girls in each group as 61.4% and 62.0% respectively. PCOS women presented with significantly higher LH, E2, and testosterone, as well as lower FSH levels. No statistical difference was observed in terms of maternal age, BMI, parity, cesarean section rate, and the incidence of PIH and GDM.

**Table 2** showed the clinical characteristics of PCOS-off. PCOS-off tended to have lower weight Z-score. Other clinical characteristics were similar between the two groups. After stratification according to sex, boys born to PCOS women (PCOS-b) showed lower TSH level compared with their counterparts (Table S1). There was no difference in other clinical features in PCOS-b, nor were all characteristics in girls born to PCOS women (PCOS-g) (Table S2).

**Lipidomics**
Lipidomics analysis identified a total of 1779 metabolites. After deleting 8 metabolites expressed in less than 50% of samples, the remained metabolites for statistical analysis were 1771. As shown
TABLE 1 | Baseline characteristics of the study population.

| Characteristics | PCOS-off (n=70) | Con-off (n=71) | P value |
|-----------------|----------------|---------------|---------|
| Maternal         |                |               |         |
| characteristics  |                |               |         |
| Age at delivery, yrs | 28.8 ± 3.1 | 28.8 ± 3.2 | 0.97    |
| BMI before pregnancy, kg/m² | 24.3 ± 3.5 | 24.2 ± 3.2 | 0.90    |
| University degree or higher, n (%) | 21 (30.3%) | 19 (26.8%) | 0.67    |
| T, ng/dl        | 40.5 (28.2-59.5) | 29.1 (17.8-36.6) | <0.001* |
| FSH, IU/L       | 5.9 (1.6-7.1) | 6.6 (5.7-7.6) | 0.001*  |
| LH, IU/L        | 7.8 (5.7-11.2) | 4.8 (3.4-6.2) | <0.001* |
| E2, pg/ml       | 39.9 (30.9-49.9) | 33.2 (24.7-41.8) | 0.004*  |
| Paternal         |                |               |         |
| characteristics  |                |               |         |
| Age at delivery, yrs | 30.2 ± 4.2 | 29.6 ± 3.2 | 0.33    |
| BMI before pregnancy, kg/m² | 22.7 ± 1.8 | 22.9 ± 1.6 | 0.49    |
| Parity           |                |               | >0.999  |
| 1, n (%)        | 67 (95.7%) | 67 (94.4%) |         |
| >2, n (%)       | 3 (4.3%)  | 4 (5.6%)   |         |
| Household income |                |               | 0.25    |
| Low, n (%)      | 44 (62.9%) | 35 (49.3%) |         |
| Medium, n (%)   | 20 (28.6%) | 29 (40.8%) |         |
| High, n (%)     | 6 (8.6%)  | 7 (9.9%)   |         |
| Cesarean, n (%) | 51 (72.9%) | 55 (77.5%) | 0.53    |
| Pih, n (%)      | 5 (7.1%)  | 2 (2.8%)   | 0.43    |
| GDM, n (%)      | 2 (2.9%)  | 2 (2.8%)   | >0.999  |
| Female offspring, n (%) | 43 (61.4%) | 44 (62.0%) | 0.95    |
| Age of offspring, yrs | 3.51 (3.2-5.16) | 3.59 (3.19-5.05) | 0.995   |

Data were shown as mean ± SD, median (interquartile range) or n (%).

Differences were assessed using Student t test or Mann-Whitney U tests for continuous variables and Chi-square tests for categorical variables.

*p<0.05 was considered statistically significant.

PCOS-off: offspring born to PCOS women; Con-off: offspring of the control group; BMI, body mass index; T, Testosterone; FSH, follicle-stimulating hormone; LH, luteinizing hormone; E2, estrogen; PRL, Prolactin; T, Testosterone; TSH, thyroid-stimulating hormone; AMH, anti-Müllerian hormone; DHEA-S, dehydroepiandrosterone sulfate; FT3, free triiodothyronine; FT4, free thyroxine; A-TG, antibodies against thyroglobulin; A-TPO, antibodies against thyroperoxidase; BG0, fasting glucose; INS0, fasting insulin; HOMA-IR, homeostasis model for insulin resistance; HOMA-β, homeostasis model for β-cell function; CHOL, total cholesterol; TG, triglycerides; LDL, low density lipoprotein cholesterol; HDL, high density lipoprotein cholesterol.

in Figure 1, plasma lipid profiles of the general offspring were revealed by the PLS-DA and volcano plot. The corresponding results for female and male offspring were shown in Supplementary Figures 1 and 2. PLS-DA scores plot showed different metabolite profiles between PCOS-off and control group. Volcanic map showed the overall distribution of differential metabolites. In total, we identified 8 categories of 44 metabolites significantly altered between the two groups in PCOS-off (Table 3), and 3 of which were previously reported having definite clinical relevance including glycerophospholipids (GP), glycolipids (GL), and sphingomyelin (SM). Among them, 8 metabolites showed higher levels with 1 GP, 1 GL, and 1SM, and the other 36 metabolites showed lower levels with 6 GP and 19 GL.

After stratification according to sex, in PCOS-g, 13 up-regulated metabolites (including 4 GP, 2 GL, and 7 other lipids) and 31 down-regulated ones (including 2 GP, 13 GL, and 16 other metabolites) were identified (Table S3). PCOS-b showed different lipids distribution presented as 9 up-regulated (1 SM and 8 others) and 35 down-regulated (16GP, 3GL, and 19 other species) (Table S4).

Association Between Lipid Metabolites and Phenotypes

In order to determine the associations of plasma lipids with clinical phenotypes, we screened the differential clinical phenotypes between the PCOS-off and the control offspring in this study, and combined them with those found in our previous studies and other studies as the outcome for linear regression analysis (12, 13). In summary, the outcome variables included maternal age and BMI [P-adjusted, 0.026; β (95%CI), -0.18 (-0.69, -0.05)].

*p<0.05 was considered statistically significant. †represents a missing data. ‡represents two missing data.

PCOS-off, offspring born to PCOS women; Con-off, offspring of the control group; BW, birth weight; GA, gestational age; BMI, body mass index; T, Testosterone; FSH, follicle-stimulating hormone; LH, luteinizing hormone; E2, estrogen; PRL, Prolactin; T, Testosterone; TSH, thyroid-stimulating hormone; AMH, anti-Müllerian hormone; DHEA-S, dehydroepiandrosterone sulfate; FT3, free triiodothyronine; FT4, free thyroxine; A-TG, antibodies against thyroglobulin; A-TPO, antibodies against thyroperoxidase; BG0, fasting glucose; INS0, fasting insulin; HOMA-IR, homeostasis model for insulin resistance; HOMA-β, homeostasis model for β-cell function; CHOL, total cholesterol; TG, triglycerides; LDL, low density lipoprotein cholesterol; HDL, high density lipoprotein cholesterol.

TABLE 2 | Clinical characteristics of the general offspring born to women with or without PCOS.

| Characteristics | PCOS-off (n=70) | Con-off (n=71) | P value |
|-----------------|----------------|---------------|---------|
| BMI, kg/m²      |                |               |         |
| T, ng/dl        |                |               |         |
| FSH, IU/L       |                |               |         |
| LH, IU/L        |                |               |         |
| E2, pg/ml       |                |               |         |
| TSH, uli/mI     |                |               |         |
| AMH, ng/ml      |                |               |         |
| DHEA-S, ug/dl   |                |               |         |
| FT3, pmol/l     |                |               |         |
| FT4, pmol/l     |                |               |         |
| A-TG, IU/ml     |                |               |         |
| A-TPO, IU/ml    |                |               |         |
| BG0, mmol/L†    |                |               |         |
| INS0, miU/L§    |                |               |         |
| HOMA-IR†        |                |               |         |
| HOMA-β§         |                |               |         |
| CHOL, mmol/L†   |                |               |         |
| TG, mmol/L†     |                |               |         |
| LDL, mmol/L†    |                |               |         |
| HDL, mmol/L†    |                |               |         |

| Data were shown as mean ± SD, median (interquartile range). Differences were assessed using Student t test or Mann-Whitney U tests for continuous variables and Chi-square tests for categorical variables. |

*The linear regression was performed to exclude the potential confounding effects of maternal age and BMI (P-adjusted, 0.026; β (95%CI), -0.18 (-0.69, -0.05)).

*p<0.05 was considered statistically significant. †represents a missing data. ‡represents two missing data.
and TSH, no plasma lipid metabolites were significantly associated with HOMA-β, HOMA-IR, INS0, and HDL.

**DISCUSSION**

In this study, we investigated lipid profile changes in PCOS-off using a lipidomics approach based on UPLC-QTOF-MS. The results revealed significant alterations in GP, GL, SM, and some unclassified lipid metabolites. Furthermore, these changes were associated with differential phenotypes in all PCOS-off, including weight Z-score and HDL level, and showed sex-dependent correlation with TG, LDL, and TSH.

As the major component of mammalian biomembranes, GP participate in various biological pathways (19). In our clinical study, 16 metabolites were reduced in PCOS-b, including phosphatidylcholines (PC), lysophosphatidylcholine (lysoPC), phosphoethanolamine (PE), and lysophosphoethanolamine (lysoPE). PC can promote both cell proliferation and programmed cell death and is known to improve insulin sensitivity (20). LysoPC is a compound produced by hydrolysis of PC, and an accumulating number of studies show that it plays a vital role in glucose homeostasis. Plasma lysoPC is decreased in T2D and obesity (21). LysoPC has also been shown to stimulate adipocyte glucose uptake and improve blood glucose levels in murine models of diabetes (22); furthermore, exogenous lysoPC can inhibit free fatty acid-induced C-Jun N-terminal kinase activation and insulin resistance (23). An additional study found that lysoPC could induce PKC-α activation and inhibit Akt activation in vascular smooth muscle cells (VSMCs) by blocking IRS-1 function suggesting a role for lysoPC in vascular insulin resistance (24). The reduction of PC and lysoPC in PCOS-b may indicate an increased risk of insulin resistance and diabetes mellitus, which was consistent with our previous study that found aberrant insulin metabolism in PCOS-b (12). However, in the present study we found no correlation between changes in GP and glucose metabolic parameters, instead, an association of GP with TSH was indicated. That may be owing to the bilateral changes of the components. The association of specific lipids, such as PC and lysoPC, with glucose metabolism in PCOS-off is worthy of future study.

SM was another identified metabolite that was significantly changed in PCOS-off in the present study. As one of the major phospholipids in the lipid microdomains it was found to be positively correlated with insulin resistance. SM synthase 2 knock-out mice have been shown to escape from high fat diet-
induced obesity and insulin resistance, while silencing of SM synthase 2 is able to reduce lipid droplets in the liver (25). Lipid rafts, which are highly enriched in SM, are thought to be essential regulators of insulin signaling (26); although the mechanism still needs to be explained through future studies. Furthermore, plasma SM mainly exists in atherogenic lipoproteins, and is correlated with the metabolism of apoB-containing or TG-rich lipoproteins (27). SM carried into the arterial wall on atherogenic lipoproteins can promote lipoprotein aggregation (28). SM has also been shown to be associated with subclinical atherosclerosis and coronary artery disease (27, 29). Therefore, our finding that increased SM levels in PCOS-off indicate an increased risk of aberrant cardiometabolic health show that SM should be carefully monitored.

### TABLE 3 | Metabolites altered between study groups in the general offspring.

| Metabolites       | VIP   | FC    | P value | Trend |
|-------------------|-------|-------|---------|-------|
| Glycerolipids [GL] |       |       |         |       |
| MG (0:0/20:4(8Z,11Z,14Z,17Z)/0:0) | 1.51  | 1.33  | 0.05    | ↑     |
| Monoelaidin       | 1.51  | 0.78  | 0.001   | ↓     |
| DG (14:0/16:0/0:0) | 2.26  | 0.75  | 0.02    | ↓     |
| DG (14:0/18:2(9Z,12Z)/0:0) | 1.66  | 0.77  | 0.01    | ↓     |
| DG (14:1/16:0/0:0) | 2.95  | 0.68  | 0.02    | ↓     |
| DG (15:0/18:1(11Z)/0:0) | 4.59  | 0.62  | 0.05    | ↓     |
| DG (16:0/16:0/0:0) | 2.27  | 0.71  | 0.05    | ↓     |
| DG (16:0/16:0/0:0) | 1.42  | 0.78  | 0.02    | ↓     |
| DG (16:0/18:3(9Z,12Z,15Z)/0:0) | 1.62  | 0.70  | 0.001   | ↓     |
| DG (12/0:14:0/18:1(9Z)) [iso6] | 3.18  | 0.54  | 0.04    | ↓     |
| DG (12/0:16:0/18:1(9Z)) [iso6] | 3.17  | 0.63  | 0.04    | ↓     |
| DG (12/0:18:2(9Z,12Z)/16:1(9Z)] [iso6] | 3.20  | 0.71  | 0.02    | ↓     |
| DG (14/0:18:2(9Z,12Z)/16:1(9Z)] [iso6] | 2.25  | 0.73  | 0.02    | ↓     |
| DG (15/0:18:2(9Z,18:2(9Z,12Z])/0:0) | 1.77  | 0.75  | 0.04    | ↓     |
| DG (15/0:18:2(9Z,18:2(9Z,12Z])/0:0) | 1.10  | 0.82  | 0.02    | ↓     |
| DG (16/0:14:0/18:1(9Z)] [iso6] | 2.14  | 0.73  | 0.05    | ↓     |
| DG (16/0:14:0/18:2(9Z,12Z)] [iso6] | 2.17  | 0.76  | 0.05    | ↓     |
| DG (16/0:15:0/18:1(11Z)] | 2.24  | 0.76  | 0.01    | ↓     |
| DG (16:0/18:4(9Z,12Z,15Z)/18:1(11Z)] | 1.15  | 0.83  | 0.04    | ↓     |
| DG (18:2(9Z,12Z)/14:0/18:3(9Z,12Z,15Z)] [iso6] | 1.70  | 0.80  | 0.02    | ↓     |
| Glycerophospholipids [GP] |       |       |         |       |
| PA (16:0/18:1(9Z)) | 1.17  | 0.80  | 0.01    | ↓     |
| PA (16:0/14:0) | 1.05  | 0.77  | 0.02    | ↓     |
| PC (16:0/20:2) | 3.70  | 1.32  | 0.001   | ↑     |
| PC (13:0/0:0) | 2.97  | 0.76  | 0.02    | ↓     |
| PI (18:3(9Z,12Z,15Z)/16:0) | 3.93  | 0.73  | 0.01    | ↓     |
| LysoPE (0:0/18:0) | 2.15  | 0.81  | 0.02    | ↓     |
| LysoPC (14:0) | 3.45  | 0.75  | 0.02    | ↓     |
| Fatty Acyls [FA] |       |       |         |       |
| 1-Tridecene | 2.23  | 0.79  | 0.002   | ↓     |
| 2-Linoleoylglycerol | 1.49  | 0.76  | 0.01    | ↓     |
| cis-Uvariacin IB | 7.28  | 1.69  | 0.02    | ↑     |
| Hexacosanoyl carnitine | 2.19  | 1.29  | 0.001   | ↑     |
| Methyl jasmonate | 4.00  | 0.75  | 0.04    | ↓     |
| Carboxylic acids and derivatives |       |       |         |       |
| L-Glutamine | 1.84  | 0.83  | 0.01    | ↓     |
| Ritphotnin A | 1.48  | 0.80  | 0.01    | ↓     |
| N-Nonanoylglycine | 3.62  | 0.71  | 0.05    | ↓     |
| Benzene and substituted derivatives |       |       |         |       |
| 3-Pentadecylphenol | 1.43  | 1.20  | 0.01    | ↑     |
| 2-Hydroxybenzaldehyde | 2.69  | 1.22  | 0.003   | ↑     |
| Prenol Lipids [PR] |       |       |         |       |
| Coenzyme Q10 | 1.12  | 1.20  | 0.003   | ↑     |
| Sphingolipids [SP] |       |       |         |       |
| SM (d16:1/23:0) | 1.82  | 1.22  | 0.001   | ↑     |
| Unclassified metabolites |       |       |         |       |
| Endosulfan-sulfate | 1.84  | 1.22  | 0.02    | ↑     |
| Bacteriohopane-31,32,33,34,35-pentol | 2.97  | 0.70  | 0.02    | ↓     |
| Progesterone, 16.alpha.-methyl- | 1.05  | 0.82  | 0.04    | ↓     |
| (24R)-25-fluoro-1alpha,24-dihydroxyvitamin D3 | 2.78  | 0.78  | 0.01    | ↓     |
| 12,13-DHOME | 3.28  | 0.76  | 0.04    | ↓     |

The threshold value was VIP > 1.0, FC > 1.2 or FC < 0.833 and P value < 0.05. The potential markers with clinical value were presented in bold. VIP, variable importance in the projection value from PLS-DA model; FC, fold change; P value was calculated by student t test.
The results of our study showed a significant decrease of GL, such as diglyceride (DG) and TG, in PCOS-g. TG and DG are reported to be associated with impaired glucose tolerance, insulin resistance, and T2D (30, 31). In plasma, elevated proportions of TG and DG are positively correlated with liver fat, visceral fat, systolic blood pressure, and insulin resistance (30). Our finding of the decreased levels of GL in PCOS-g may indicate the lower risk of insulin resistance, diabetes, and obesity, which was consistent with some recent studies. Li et al. (12) compared PCOS-g with normal girls and found no difference in glucose or lipid profiles. A further individual participant data meta-analysis indicated a healthy performance of lipids in PCOS-g, including decreased LDL and CHOL, as well as increased HDL levels (13). Protection of E2 may be an explanation. The correlation between GL components and serum TG levels was also confirmed in the present study which indicated the possible protective effect of E2 on lipid profiles. However, the meta-analysis showed increased after-loaded insulin levels in PCOS-g, which was contradictory with changes in metabolites (13). Similarly, PCOS women also show reduced GL levels (32), which may be explained by differential lipid structure. Lipids with lower carbon number and double bond content have been found to be associated with a higher risk of diabetes and vice versa (33). Furthermore, PCOS subtypes may also have varied lipid profiles. Finally, obese PCOS women show increased lipolysis, while nonobese PCOS women present with decreased lipolysis and enhanced glucose utilization in peripheral tissues (34). Therefore, the effect of changes in GL level on PCOS-g remain to be elucidated.

Strengths of the current study include its comprehensive view of lipid profiles in PCOS-off, generated using a lipidomics approach, and its identification of sex specific changes of the lipid metabolites. A series of changes were found in the metabolism and endocrinology of PCOS-off, such as birth weight, HDL, AMH, and TSH, some of which differed according to sex (12, 13). The results built a link between biomolecular changes and clinical phenotypes, which suggested potential sensitive markers for the early detection of aberrant cardiometabolic events in this well-accepted susceptible population, along with new indications in pathogenesis studies of relative disorders. However, our study also had several limitations. Firstly, the relatively small sample size after stratification according to sex limited the statistical power. Secondly, carboxylic acids and derivatives, as well as PR and some unclassified metabolites also showed significant changes in PCOS-off, and some of them presented with sex differences. However, the category and function of these metabolites were not detected and their potential impact was not clear. The mechanism of these metabolites involved in PCOS related phenotypic changes needs to be further explored. Although hundreds of differential lipids were found in this lipidomics analysis, other species of metabolites are not included and await further broader studies. Moreover, although we adjusted some confounding factors, other potential confounding maternal factors, such as smoking, drinking, and breastfeeding, were not included in the present study owing to the lack of data. Furthermore, the number of cases of some confounding
factors, such as GDM, were relatively small, which may limit the statistical power in multiple regression analysis.

In conclusion, we observed that PCOS-off already presented specific lipid profile alterations during childhood, before significant differences were detected by regular clinical metabolic screening tests. The abnormal level of GP and SM indicated the risk of glucose metabolism and cardiovascular diseases in PCOS-off. This susceptible population therefore needs more specific and detailed monitoring and management. Lipid metabolites, such as PC, lysoPC, and SM identified using rapid detection kits, are suggested as potential markers. Their pathogenic roles need to be elucidated in future functional studies.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by The institutional ethics committee of Shandong University. Written informed consent to participate in this study was provided by the participants’ legal guardian/next of kin.

REFERENCES

1. Rubin KH, Glintborg D, Nybo M, Abrahamsen B, Andersen M. Development and Risk Factors of Type 2 Diabetes in a Nationwide Population of Women With Polycystic Ovary Syndrome. J Clin Endocrinol Metab (2017) 102:3848–57. doi: 10.1210/jc.2017-01354
2. Moran LJ, Misso ML, Wild RA, Norman RJ. Impaired Glucose Tolerance, Type 2 Diabetes and Metabolic Syndrome in Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis. Hum Reprod Update (2010) 16:347–63. doi: 10.1093/humupd/dmp001
3. Fauser BC, Tarlatzis BC, Rebar RW, Legro RS, Balem AH, Lobo R, et al. Consensus on Women’s Health Aspects of Polycystic Ovary Syndrome (PCOS): The Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril (2012) 97:28–38.e25. doi: 10.1016/j.fertnstert.2011.09.024
4. Palomba S, Falbo A, Chiossi G, Orio F, Tolino A, Colao A, et al. Low-Grade Chronic Inflammation in Pregnant Women With Polycystic Ovary Syndrome: A Prospective Controlled Clinical Study. J Clin Endocrinol Metab (2014) 99:2942–51. doi: 10.1210/jc.2014-1214
5. Boomsma CM, Eijkemans MJ, Hughes EG, Visser GH, Fauser BC, Macklon NS. A Meta-Analysis of Pregnancy Outcomes in Women With Polycystic Ovary Syndrome. Hum Reprod Update (2006) 12:673–83. doi: 10.1093/humupd/dm6036
6. Dumesic DA, Goodarzi MO, Chazenbalk GD, Abbott DH. Intrauterine Environment and Polycystic Ovary Syndrome. Semin Reprod Med (2014) 32:159–65. doi: 10.1055/s-0034-1371087
7. Koster MP, de Wilde MA, Veltman-Verhulst SM, Houben ML, Nikkiels PG, van Rijn BB, et al. Placental Characteristics in Women With Polycystic Ovary Syndrome. Hum Reprod (2015) 30:2829–37. doi: 10.1093/humrep/dev265
8. Palomba S, de Wilde MA, Falbo A, Koster MP, La Sala GB, Fauser BC. Pregnancy Complications in Women With Polycystic Ovary Syndrome. Hum Reprod Update (2015) 21:575–92. doi: 10.1093/humupd/dmv029
9. Barker DJ, Osmond C, Golding J, Kuh D, Wadsworth ME. Growth in Utero, Blood Pressure in Childhood and Adult Life, and Mortality From Cardiovascular Disease. BMJ (1989) 298:564–7. doi: 10.1136/bmj.298.6763.564
10. Kermack AJ, Van Rijn BB, Houghton FD, Calder PC, Cameron IT, Macklon NS. The ‘Developmental Origins’ Hypothesis: Relevance to the Obstetrician and Gynecologist. J Dev Orig Health Dis (2015) 6:645–24. doi: 10.1017/S2040174415001324
11. Pauw ND, van Rijn BB, Lely AT, Joles JA. Pregnancy as a Critical Window for Blood Pressure Regulation in Mother and Child: Programming and Reprogramming. Acta Physiol (Oxf) (2017) 219:241–59. doi: 10.1111/apha.12702
12. Li J, Cui L, Jiang X, Zhao H, Zhao S, Shi Y, et al. Transmission of Polycystic Ovary Syndrome Susceptibility Single-Nucleotide Polymorphisms and Their Association With Phenotype Changes in Offspring. Hum Reprod (2020) 35:1711–8. doi: 10.1093/humrep/deaa125
13. Gunning MN, Sir Petermann T, Crisosto N, van Rijn BB, de Wilde MA, Christ JP, et al. Cardiometabolic Health in Offspring of Women With PCOS Compared to Healthy Controls: A Systematic Review and Individual Participant Data Meta-Analysis. Hum Reprod Update (2020) 26:103–17. doi: 10.1093/humupd/dmz036
14. Maliqueo M, Echiburu B, Crisosto N, Amigo P, Aranda P, Sanchez F, et al. Metabolic Parameters in Cord Blood of Newborns of Women With Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis. Hum Reprod Update (2017) 23:107–26. doi: 10.1093/humupd/dmv045
15. Coughlin SS. Toward a Road Map for Global -Omics: A Primer on -Omic Technologies. J Clin Lipidol (2017) 11:107–20. doi: 10.1016/j.jclnl.2017.04.005
16. Abdel-Maksoud MF, Eckel RH, Hamman RF, Hokanson JE. Risk of Coronary Heart Disease is Associated With Triglycerides and High-Density Lipoprotein Cholesterol in Women and Non-High-Density Lipoprotein Cholesterol in Men. J Clin Lipidol (2012) 6:374–81. doi: 10.1016/j.jclnl.2012.02.011
17. Navar AM. The Evolving Story of Triglycerides and Coronary Heart Disease Risk. JAMA (2019) 321:347–9. doi: 10.1001/jama.2018.20044

AUTHOR CONTRIBUTIONS

HZ and LC designed the study. YL selected the study population and collected plasma samples. ZZ and YL drafted the manuscript. DZ, JL, KH and JM collected clinical data used in the study. JLv performed statistical analysis. HZ, LC, ZZ and YL participated in the revision and final approval of the manuscript. All authors contributed to the article and approved the submitted version.

FUNDING

This work was supported by The National Key Research and Development Program of China 2016YFC1000200 and 2016YFC10002004, 2018YFC1004301, Basic Science Center Program of NSFC 31988101, Shandong Provincial Key Research and Development Program 2018YJH0504, and Shandong Province Medical and Health Technology Development Project 2016WS0368. The sponsors had no role in this study.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fendo.2021.698734/full#supplementary-material
19. Exton JH. Phosphatidylcholine Breakdown and Signal Transduction. *Biochim Biophys Acta* (1994) 1212:26–42. doi: 10.1016/0005-2760(94)90186-4
20. Ridgway ND. The Role of Phosphatidylcholine and Choline Metabolites to Cell Proliferation and Survival. *Crit Rev Biochem Mol Biol* (2013) 48:20–38. doi: 10.3109/10409238.2012.735643
21. Barber MN, Rissi S, Yang C, Meikle PJ, Staples M, Febbraio MA, et al. Plasma Lysophosphatidylcholine Levels Are Reduced in Obesity and Type 2 Diabetes. *PLoS One* (2012) 7:e41456. doi: 10.1371/journal.pone.0041456
22. Ye A, Kim J, Yoon JH, Kwon T, Kim JH, Lee BD, et al. Lysophosphatidylcholine Activates Adipocyte Glucose Uptake and Lowers Blood Glucose Levels in Murine Models of Diabetes. *J Biol Chem* (2009) 284:33833–40. doi: 10.1074/jbc.M109.024869
23. Han MS, Lim YM, Quan W, Kim JR, Chung KW, Kang M, et al. Lysophosphatidylcholine as an Effector of Fatty Acid-Induced Insulin Resistance. *J Lipid Res* (2011) 52:1234–46. doi: 10.1194/jlr.M014787
24. Motley ED, Kibir SM, Gardner CD, Eguchi K, Frank GD, Kuroki T, et al. Lysophosphatidylcholine Inhibits Insulin-Induced Akt Activation Through Protein Kinase C-Alpha in Vascular Smooth Muscle Cells. *Hypertension* (2002) 39:508–12. doi: 10.1161/01.hyp.102907
25. Mitsutake S, Zama K, Yokota H, Yoshida T, Tanaka M, Mitsui M, et al. Dynamic Modification of Sphingomyelin in Lipid Microdomains Controls Development of Obesity, Fatty Liver, and Type 2 Diabetes. *J Biol Chem* (2011) 286:28544–55. doi: 10.1074/jbc.M111.255646
26. Li Z, Zhang H, Liu J, Liang CP, Li Y, Li Y, et al. Reducing Plasma Membrane Sphingomyelin Increases Insulin Sensitivity. *Mol Cell Biol* (2011) 31:A205–18. doi: 10.1128/MCB.05893-11
27. Schlicht A, Blankenberg S, Yann D, von Guzycki H, Buerke M, Wedan K, et al. Further Evaluation of Plasma Sphingomyelin Levels as a Risk Factor for Coronary Artery Disease. *Nutr Metab (Lond)* (2006) 3:5. doi: 10.1186/1743-7075-3-5
28. Schessel SL, Tweede-Hardman J, Rapp JH, Graham G, Williams KJ, Tabas J, Rabbit Aorta and Human Atherosclerotic Lesions Hydrolyze the Sphingomyelin of Retained Low-Density Lipoprotein. Proposed Role for Arterial-Wall Sphingomyelinase in Subendothelial Retention and Aggregation of Atherogenic Lipoproteins. *J Clin Invest* (1996) 98:1455–64. doi: 10.1172/JCI18934
29. Jung XC, Paulthe F, Pearson TA, Reed BG, Francis CK, Lin M, et al. Plasma Sphingomyelin Level as a Risk Factor for Coronary Artery Disease. *Arterioscler Thromb Vasc Biol* (2000) 20:2614–8. doi: 10.1161/01.atv.20.12.2614
30. Tonk KT, Coster AC, Christopher MJ, Chaudhuri R, Xu A, Gagnon-Bartsch J, et al. Skeletal Muscle and Plasma Lipidic Signatures of Insulin Resistance and Overweight/Obesity in Humans. *Obes (Silver Spring)* (2016) 24:908–16. doi: 10.1002/oby.21448
31. Meikle PJ, Wong G, Barlow CK, Weir JM, Greeve MA, MacIntosh GL, et al. Plasma Lipid Profiling Shows Similar Associations With Prediabetes and Type 2 Diabetes. *PLoS One* (2013) 8:e74341. doi: 10.1371/journal.pone.0074341
32. Jove M, Pradas I, Naudi A, Rovira-Llopis S, Bañuls C, Rocha M. Lipidomics Reveals Altered Biosynthetic Pathways of Glyceroprophospholipids and Cell Signaling as Biomarkers of the Polycystic Ovary Syndrome. *Oncotarget* (2017) 9:4522–36. doi: 10.18632/oncotarget.23393
33. Rhee EP, Cheng S, Larson MG, Walford GA, Lewis GD, McCabe E, et al. Lipid Profiling Identifies a Triacylglycerol Signature of Insulin Resistance and Improves Diabetes Prediction in Humans. *J Clin Invest* (2011) 121:1402–11. doi: 10.1172/JCI44442
34. Escobar-Morreale HF, Samino S, Insenser M, Vinaixa M, Luque-Ramirez M, Lasuncion MA, et al. Metabolic Heterogeneity in Polycystic Ovary Syndrome is Determined by Obesity: Plasma Metabolomic Approach Using GC-MS. *Clin Chem* (2012) 58:999–1009. doi: 10.1373/clinchem.2011.176396

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Zhang, Liu, Lv, Zhang, Hu, Li, Ma, Cui and Zhao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.